doi: 10.1126/science.271.5256.1734.
Enhancement of antitumor immunity by CTLA-4 blockade
Affiliations
- PMID: 8596936
- DOI: 10.1126/science.271.5256.1734
Item in Clipboard
Enhancement of antitumor immunity by CTLA-4 blockade
Science.
.
Abstract
One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.
Comment in
-
Releasing the brakes on antitumor immune response.Science. 1996 Mar 22;271(5256):1691. doi: 10.1126/science.271.5256.1691. Science. 1996. PMID: 8596929 No abstract available.
Similar articles
-
CD28-independent costimulation of T cells in alloimmune responses.J Immunol. 2001 Jul 1;167(1):140-6. doi: 10.4049/jimmunol.167.1.140. J Immunol. 2001. PMID: 11418642
-
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.Cell. 1992 Dec 24;71(7):1093-102. doi: 10.1016/s0092-8674(05)80059-5. Cell. 1992. PMID: 1335364
-
The complexity of the B7-CD28/CTLA-4 costimulatory pathway.Agents Actions Suppl. 1998;49:33-43. doi: 10.1007/978-3-0348-8857-8_6. Agents Actions Suppl. 1998. PMID: 9426826 Review.
-
Absence of B7-dependent responses in CD28-deficient mice.Immunity. 1994 Sep;1(6):501-8. doi: 10.1016/1074-7613(94)90092-2. Immunity. 1994. PMID: 7534617
-
The Yin and Yang of T cell costimulation.Science. 1995 Nov 10;270(5238):932-3. doi: 10.1126/science.270.5238.932. Science. 1995. PMID: 7481795 Review. No abstract available.
Cited by
-
Bioceramics Enhance the Anti-Tumor Activity of Immune Cells in Adoptive Immunotherapy.Int J Mol Sci. 2024 Sep 30;25(19):10567. doi: 10.3390/ijms251910567. Int J Mol Sci. 2024. PMID: 39408898 Free PMC article.
-
Rapid turnover of CTLA4 is associated with a complex architecture of reversible ubiquitylation.J Cell Biol. 2025 Jan 6;224(1):e202312141. doi: 10.1083/jcb.202312141. Epub 2024 Oct 15. J Cell Biol. 2025. PMID: 39404738 Free PMC article.
-
Advantages of the zebrafish tumor xenograft model: the evaluation of efficacy in cancer therapy and the application to the study of lncRNAs.Front Immunol. 2024 Sep 30;15:1483192. doi: 10.3389/fimmu.2024.1483192. eCollection 2024. Front Immunol. 2024. PMID: 39403375 Free PMC article. Review.
-
The effect of radiotherapy, chemotherapy, and immunotherapy on fusion rate in spinal surgery using osteobiologics for patients with metastatic spinal disease: a systematic review.Neurosurg Rev. 2024 Oct 15;47(1):796. doi: 10.1007/s10143-024-02769-3. Neurosurg Rev. 2024. PMID: 39402387 Review.
-
Gastric Cancer Signaling Pathways and Therapeutic Applications.Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241271935. doi: 10.1177/15330338241271935. Technol Cancer Res Treat. 2024. PMID: 39376170 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
